FDA Approves New Generic Treatment for Asthma, COPD

Published Online: Wednesday, January 30th, 2019
The FDA has approved the first generic version of Advair Diskus (GlaxoSmithKline), a fluticasone propionate and salmeterol inhalation powder product. Approved for 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg doses, the generic drug (Wixela Inhub, Mylan) is indicated to treat patients with asthma and chronic obstructive pulmonary disease (COPD), including bronchitis and emphysema.

The newly approved fluticasone propionate and salmeterol inhalation powder contains a corticosteroid and a long-acting beta(2)-adrenergic agonist (LABA) indicated for twice daily treatment of asthma in patients aged 4 years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD. This medicine is a complex drug-device combination product for which no generic product has been previously approved by FDA.

Generic drugs are approved once they have met FDA’s rigorous approval standards to ensure the generic drug is as safe and effective as the brand name drug product. The generic must also meet the same quality requirements for manufacturing and packaging as the brand name drug product. FDA expedited the review of this abbreviated new drug application (ANDA) as a potential first generic.

In the United States, 26 million people, including children, have asthma and 16 million people are living with COPD. According to the FDA, today’s approval should provide greater patient access to this medication.

This article was originally published at PharmacyTimes.com


FDA approves first generic Advair Diskus [news release]. Silver Spring, MD; January 30, 2019: FDA website. http://www.pharmacytimes.com/link/251. Accessed January 30, 

Current Issue

The Educated Patient

Jennifer L. Hofmann, MS, PA-C
Providing them with advice can improve control of the disease and reduce hospitalizations, morbidity, and unscheduled health care visits.
Emily C. Hayes, PharmD Candidate
Colds, coughs, and a relentless influx of sick patients in retail health clinics keep the health care providers who work there very busy.
Kristen Marjama, DNP, APRN-BC
Although the rate of foot and leg amputation has greatly declined over the past 2 decades, increasing awareness for macrovascular and microvascular complications of diabetes is essential because diabetes is the leading cause of lower-limb amputations in the United States.
Kristen Marjama, DNP, FNP-BC
Gluten proteins found in barley, rye, and wheat trigger systemic injury primarily to the small intestine, but they can also affect the joints, liver, skin, uterus, and other organs.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Contact Us
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2018
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.